Literature DB >> 28475845

Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas.

Sourya Shrestha1, Andrew N Hill2, Suzanne M Marks2, David W Dowdy1.   

Abstract

RATIONALE: There is substantial state-to-state heterogeneity in tuberculosis (TB) in the United States; better understanding this heterogeneity can inform effective response to TB at the state level, the level at which most TB control efforts are coordinated.
OBJECTIVES: To characterize drivers of state-level heterogeneity in TB epidemiology in the four U.S. states that bear half the country's TB burden: California, Florida, New York, and Texas.
METHODS: We constructed an individual-based model of TB in the four U.S. states and calibrated the model to state-specific demographic and age- and nativity-stratified TB incidence data. We used the model to infer differences in natural history of TB and in future projections of TB.
MEASUREMENTS AND MAIN RESULTS: We found that differences in both demographic makeup (particularly the size and composition of the foreign-born population) and TB transmission dynamics contribute to state-level differences in TB epidemiology. The projected median annual rate of decline in TB incidence in the next decade was substantially higher in Texas (3.3%; 95% range, -5.6 to 10.9) than in California (1.7%; 95% range, -3.8 to 7.1), Florida (1.5%; 95% range, -7.4 to 14), and New York (1.9%; 95% range, -6.4 to 9.8). All scenarios projected a flattening of the decline in TB incidence by 2025 without additional resources or interventions.
CONCLUSIONS: There is substantial state-level heterogeneity in TB epidemiology in the four states, which reflect both demographic factors and potential differences in the natural history of TB. These differences may inform resource allocation decisions in these states.

Entities:  

Keywords:  geographical heterogeneity in tuberculosis; mathematical modeling of tuberculosis; tuberculosis; tuberculosis in the United States

Mesh:

Year:  2017        PMID: 28475845      PMCID: PMC5808932          DOI: 10.1164/rccm.201702-0377OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  20 in total

1.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

Authors:  C Dye; G P Garnett; K Sleeman; B G Williams
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

2.  Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example.

Authors:  M A Sanchez; S M Blower
Journal:  Am J Epidemiol       Date:  1997-06-15       Impact factor: 4.897

3.  A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States.

Authors:  Anne Marie France; Juliana Grant; J Steve Kammerer; Thomas R Navin
Journal:  Am J Epidemiol       Date:  2015-10-13       Impact factor: 4.897

4.  Revisiting rates of reactivation tuberculosis: a population-based approach.

Authors:  C Robert Horsburgh; Max O'Donnell; Sandra Chamblee; Janet L Moreland; Johnny Johnson; Bryan J Marsh; Masahiro Narita; Linda Scoles Johnson; C Fordham von Reyn
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

5.  Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.

Authors:  Laith J Abu-Raddad; Lorenzo Sabatelli; Jerusha T Achterberg; Jonathan D Sugimoto; Ira M Longini; Christopher Dye; M Elizabeth Halloran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

6.  Interpreting the decline in tuberculosis: the role of secular trends in effective contact.

Authors:  E Vynnycky; P E Fine
Journal:  Int J Epidemiol       Date:  1999-04       Impact factor: 7.196

7.  The impact of immigration on the elimination of tuberculosis in The Netherlands: a model based approach.

Authors:  den Bosch J H Wolleswinkel-van; N J D Nagelkerke; J F Broekmans; M W Borgdorff
Journal:  Int J Tuberc Lung Dis       Date:  2002-02       Impact factor: 2.373

8.  The intrinsic transmission dynamics of tuberculosis epidemics.

Authors:  S M Blower; A R McLean; T C Porco; P M Small; P C Hopewell; M A Sanchez; A R Moss
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

9.  Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup.

Authors:  Kimberly M Shea; J Steve Kammerer; Carla A Winston; Thomas R Navin; C Robert Horsburgh
Journal:  Am J Epidemiol       Date:  2013-10-18       Impact factor: 4.897

10.  Projection of tuberculosis incidence with increasing immigration trends.

Authors:  Yicang Zhou; Kamran Khan; Zhilan Feng; Jianhong Wu
Journal:  J Theor Biol       Date:  2008-05-29       Impact factor: 2.691

View more
  15 in total

1.  Changes in Tuberculosis Disparities at a Time of Decreasing Tuberculosis Incidence in the United States, 1994-2016.

Authors:  Awal Khan; Suzanne Marks; Dolly Katz; Sapna Bamrah Morris; Lauren Lambert; Elvin Magee; Sloane Bowman; Gail Grant
Journal:  Am J Public Health       Date:  2018-11       Impact factor: 9.308

2.  Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.

Authors:  Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

3.  Modeling the Impact of Recommendations for Primary Care-Based Screening for Latent Tuberculosis Infection in California.

Authors:  Andrea Parriott; James G Kahn; Haleh Ashki; Adam Readhead; Pennan M Barry; Alex J Goodell; Jennifer Flood; Priya B Shete
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

Review 4.  Epidemiology of Tuberculosis in the United States.

Authors:  Adam J Langer; Thomas R Navin; Carla A Winston; Philip LoBue
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 2.878

5.  Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis.

Authors:  Sourya Shrestha; Sarah Cherng; Andrew N Hill; Sue Reynolds; Jennifer Flood; Pennan M Barry; Adam Readhead; Margaret Oxtoby; Michael Lauzardo; Tom Privett; Suzanne M Marks; David W Dowdy
Journal:  Am J Epidemiol       Date:  2019-09-01       Impact factor: 4.897

6.  Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.

Authors:  Nicolas A Menzies; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Emory Wolf; Suzanne M Marks; Joshua A Salomon
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

Review 7.  Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States.

Authors:  Amit S Chitnis; Ramsey Cheung; Robert G Gish; Robert J Wong
Journal:  J Immigr Minor Health       Date:  2021-06-23

8.  Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015.

Authors:  Sarah T Cherng; Sourya Shrestha; Sue Reynolds; Andrew N Hill; Suzanne M Marks; Jane Kelly; David W Dowdy
Journal:  Am J Public Health       Date:  2018-11       Impact factor: 9.308

9.  Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas.

Authors:  Youngji Jo; Sourya Shrestha; Isabella Gomes; Suzanne Marks; Andrew Hill; Garrett Asay; David Dowdy
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

10.  Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.

Authors:  Nicolas A Menzies; Andrea Parriott; Sourya Shrestha; David W Dowdy; Ted Cohen; Joshua A Salomon; Suzanne M Marks; Andrew N Hill; Carla A Winston; Garrett R Asay; Pennan Barry; Adam Readhead; Jennifer Flood; James G Kahn; Priya B Shete
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.